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Abstract
Background: In mechanically ventilated preterm infants with respiratory distress syndrome (RDS), exogenous
surfactant application has been demonstrated both to decrease DNA-synthesis but also and paradoxically to
increase epithelial cell proliferation. However, the effect of exogenous surfactant has not been studied directly on
alveolar type II cells (ATII cells), a key cell type responsible for alveolar function and repair.
Objective: The aim of this study was to investigate the effects of two commercially available surfactant
preparations on ATII cell viability and DNA synthesis.
Methods: Curosurf
® and Alveofact
® were applied to two ATII cell lines (human A549 and mouse iMATII cells) and
to primary rat ATII cells for periods of up to 24 h. Cell viability was measured using the redox indicator resazurin
and DNA synthesis was measured using BrdU incorporation.
Results: Curosurf
® resulted in slightly decreased cell viability in all cell culture models. However, DNA synthesis
was increased in A549 and rat ATII cells but decreased in iMATII cells. Alveofact
® exhibited the opposite effects on
A549 cells and had very mild effects on the other two cell models.
Conclusion: This study showed that commercially available exogenous surfactants used to treat preterm infants
with RDS can have profound effects on cell viability and DNA synthesis.
Background
Respiratory Distress Syndrome (RDS) is caused by sur-
factant deficiency and is a leading cause of mortality
and morbidity in preterm newborns. Some infants
develop the chronic lung disease, bronchopulmonary
dysplasia (BPD), which is a major cause of long term
morbidity [1]. BPD, as described by Northway [2], is
mainly caused by a pulmonary injury associated with
mechanical ventilation [3]. The subsequent histological
correlate is characterised by cellular proliferation and
fibrosis at the alveolar level [4,5]. Another entity of
chronic lung disease is “New BPD” which occurs even
without any mechanical ventilation. New BPD is charac-
terized by abnormal development of alveolar and capil-
lary structures [5].
A key finding in both forms of chronic lung disease is
an abnormal cellular proliferation in cells of the alveo-
lus. Type II pneumocytes (ATII cells) are one of the
major alveolar cell types and function to synthesise,
secrete and recycle surfactant, and are also involved in
immunological processes. In response to lung injury,
ATII cells proliferate and differentiate into type I cells
to maintain the alveolar structure and function [6].
However, it is still poorly understood which factors
affect their differentiation and proliferation [7].
Administration of exogenous surfactant represents the
established therapy of RDS. Exogenous surfactant does
not only reduce surface tension, but has also been
shown to suppress proliferation of lymphocytes in a
concentration dependent manner [8]. In isolated fibro-
blasts, surfactant causes a decrease of DNA-synthesis
[9]. Observations in autopsies from infants with BPD
suggested a possible acceleration of epithelial cell regen-
eration in those receiving surfactant [10]. Another study
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dysplasia in infants treated with surfactant [11]. In con-
trast, a third study did not find differences with respect
to cellular proliferation and metaplasia between surfac-
tant-treated and control infants [12].
In summary, the information on the effect of surfac-
tant on ATII cell proliferation is inconsistent and has
not been studied on the cellular level to date. Therefore,
the present study was performed in cultured ATII cells
to investigate potential mitogenic or toxic effects of two
commercial surfactant preparations.
Methods
Materials
All materials were of the highest analytical grade and
were purchased from Sigma, Vienna, Austria, unless
otherwise stated. Curosurf
® (Nycomed, Vienna, Austria)
is produced from minced porcine lungs and Alveofact
®
(Boehringer-Ingelheim, Biberach, Germany) is obtained
from bovine lung lavage. Both preparations contain sur-
factant associated proteins B and C, however, at differ-
ent concentrations. Furthermore, the lipid composition
and concentration differ between both preparations [13].
Cell cultures
A549 cells: This human epithelial type II-like cell line
was cultured in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) supplemented with 7% foetal calf serum (FCS),
100 U/ml penicillin G and 100 μg/ml streptomycin at
37°C. A549 cells were obtained from ATCC (American
Tissue Culture Collection, USA).
Mouse cells: The immortal mouse alveolar type II cells
(iMATII) were obtained from the original developing
laboratory [14]. iMATII cells were seeded on human
collagen IV (5 μg/cm²) coated cell culture dishes (den-
sity of 5 × 10
5 cells/ml) in DMEM with 5 mM glucose,
supplemented with 7% FCS, 10 ng/ml human Epithelial
Growth Factor (EGF) and 10 ng/ml mouse interferon
gamma. Cells were incubated at 33°C in DMEM med-
ium (100 U/ml penicillin G and 100 μg/ml streptomy-
cin, 10 nM dexamethasone, 0.1 mM 8-bromoadenosine
3’,5’-cyclic monophosphate cAMP, and 0.1 mM isobutyl-
methylxanthine [15].
Rat cells: Rat ATII (RTII) cells were isolated from male
Sprague-Dawley rats (200 g), according to the procedure
of Dobbs et al. [16] with slight modifications as described
by Haller et al. [17]. Animal care and use were approved
by the Institutional Animal Care and Use Committee of
the Innsbruck Medical University (ZI A 07/3456). In
short, lungs were cleared of blood by perfusion and
removed from the thorax. After lavage, the lungs were
instilled with elastase solution (30 units/ml), incubated at
37°C, and minced in the presence of DNase. After stop-
ping the elastase reaction by addition of FCS, the cell
suspension was sequentially filtered and centrifuged. The
cell pellet was re-suspended in DMEM and panned on
IgG-coated plastic dishes at 37°C to remove macro-
phages. Cells were centrifuged, suspended in DMEM
supplemented with 10% FCS, 100 units/ml penicillin, 100
μg/ml streptomycin, and 24 mM NaHCO3 and cultured
in 95% humidified air and 5% CO2 at 37°C.
After cell preparation, cells were plated at a density of
4×1 0
4 cells/ml in 96 well plates (Sarstedt, Nümbrecht,
Germany) and were incubated at 37°C.
Surfactant incubation
After 24 h, cells were washed twice with DMEM to remove
non-adherent cells. Confluency was in the range of 60-70%.
Thereafter, surfactant was added for the long term incuba-
tion (24 h; Figure 1). Short term incubations (0.5 and 4 h)
were started after 23.5 or 20 h, respectively. Curosurf
® or
Alveofact
® was diluted with DMEM to achieve a final con-
centration of 10 mg phospholipids per ml [18]. At treat-
ment time, medium was removed from the wells and
replaced by 150 μl of the diluted surfactants. For controls,
cells were incubated with fresh DMEM alone.
Determination of cell viability
The amount of viable cells was measured by tracing the
metabolic conversion of resazurin to resorufin. Cells
were incubated with 150 μlD M E Mc o n t a i n i n g4 4μM
resazurin for 60 min as previously described [19] Viable
cells convert resazurin to the fluorescent metabolite
resorufin, which was measured at 540 nm excitation and
590 nm emission using a fluorescence plate reader
(GENios Plus, Tecan, Austria).
Determination of DNA synthesis
For measurement of DNA synthesis, a commercially
available BrdU assay (Roche, Mannheim, Germany) was
used as previously described [19]. The assay is based on
BrdU incorporation into the DNA of proliferating cells.
Statistics
Experiments were performed in triplicate with each cell
type and treatment; each experiment had eight technical
replicates. Differences between each surfactant prepara-
tion and controls were analyzed with the unpaired Stu-
dent’s t-test. A p < 0.05 vs. control was considered as
statistically significant. The results are expressed as per-
centage of the value of DMEM-incubated control cells
o ft h es a m ee x p e r i m e n t .A l ld a t aa r er e p r e s e n t e da s
arithmetic means + standard errors of the means (SEM).
Results
Effects of incubation time
Curosurf
® exposure resulted in a time dependent
decrease in cell viability in all cell models (Figure 2A)
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and RPII cells, but a time dependent decrease in iMATII
cells (Figure 2B). Alveofact
® exposure had no apparent
temporal effect in cell viability in any of the cell culture
models tested (Figure 3, A and 3B). However, Alveo-
fact
® exposure resulted in a stimulation of DNA synth-
esis at 4 h in A549 cells, which was significantly
inhibited at 24 h. Viability of control cells increased in
all cell models after 24 hours, but not after 4 hours
(Table 1.).
Effect of surfactant on different cell models
Cell model differences were evident with both surfactant
preparations. Curosurf
® had opposite effects on DNA
synthesis, stimulating A549 and RPII cells, while inhibit-
ing iMATII cells (Figure 2B). Alveofact
® exposure
showed comparable results with the iMATII and RPII
cells, having little effect on cell viability and no effect on
DNA synthesis, whereas in A549 cells, Alveofact
®
caused an apparent increase in cell viability and time-
dependently affected DNA synthesis (Figure 3A and 3B).
DNA synthesis of control cells increased in A549 and
MPII cells after 24 hours (Tab. 1).
Discussion
Preterm infants with RDS are treated with exogenous
surfactant. Surfactant has been shown to affect prolifera-
tion and DNA synthesis in fibroblasts and lymphocytes
[8,9]. Furthermore, surfactant treatment may accelerate
epithelial cell regeneration in mechanically ventilated
preterm infants with RDS [10]. The present study
investigated the effect of exogenous surfactant on DNA
synthesis of isolated rat ATII cells and ATII like cells
(A549) and mouse type II cells (iMATII). We demon-
strated that exogenous surfactant alters DNA synthesis
and viability of cultured type II cells differentially. The
effect of surfactant on both viability and DNA synthesis
was dependent on the duration of contact, type of sur-
factant and species of origin of ATII cells.
Duration of surfactant incubation affected mainly incor-
poration of BrdU into the cells, a surrogate of DNA synth-
esis and cell proliferation, and to a lesser extent cellular
viability. The mechanism of surfactant-mediated altera-
tions in cellular viability and its relation to proliferation
are complex, and a direct correlation between cell viability
and DNA synthesis cannot be expected in all situations,
also in control cells. The resazurin assay measures cellular
redox potential, which, for the most part, is an excellent
indicator of cell viability. However, exogenous stimuli may
result in an increase in cellular redox potential which may
also be considered as a perturbation of cellular function
whilst not directly related to cell viability or number. This
might explain the seemingly paradoxical situation of an
increased DNA synthesis despite an increased apparent
viability, particularly seen in the A549 cells. Alternatively,
a decrease in cell viability may directly stimulate cellular
proliferation as occurs in tissue repair. This effect is seen
with Curosurf
® in A549 cells. Finally, cellular damage in
the absence of repair will result in a direct correlation of
these parameters, decreased cell number and decreased
DNA synthesis, as might be the case in iMATII cells trea-
ted with Curosurf
®.
Figure 1 Rat ATII cells imaged by phase contrast (left) and fluorescence (480 nm), 24 h after incubation with Curosurf
®. Intracellular
Lamellar Bodies, the characteristic surfactant storing organelles, were stained with 500 nM LysoTracker Green DND-26. Noticeable morphological
differences to control cells were not detected.
Wemhöner et al. BMC Pulmonary Medicine 2011, 11:11
http://www.biomedcentral.com/1471-2466/11/11
Page 3 of 7Various commercially available surfactant preparations
are used to treat RDS in preterm infants. Whereas sur-
face tension lowering properties seem to be similar,
other properties such as biochemical composition, mor-
phological organisation and immunological functions
differ. Native surfactants contain SP-A/B/C and SP-D,
1.5% SP-B and 2.8 to 4.5% SP-C per μmol phospholi-
pids. Commercial surfactants contained only one half to
one third of these proteins as compared with native sur-
factants and no SP-A and SP-D components [20].
Figure 2 Effect of Curosurf
® on viability and DNA synthesis. Cells were exposed to 10 mg/ml Curosurf
® for 0.5, 4.0 and 24 h as described.
A: Viability as percentage of control. B: DNA synthesis as percentage of control. Bars represent mean + SEM of 3 independent experiments. * P
<0.05 vs. control. MPII: mouse type II (iMATII) cells, RPII: rat type II cells.
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the present study, the effect of Curosurf
® and Alveo-
fact
® was not the same. Surfactant lipids affect the fluid-
ity of cellular membranes and could thus alter cellular
pathways [9,21]. Higher concentrations of polyunsatu-
rated fatty acid-containing phospholipids (PUFA-PL)
were found in Curosurf
® compared with Alveofact
®.
They also have a difference in surface viscosity. Curo-
surf
®, with the highest plasmalogen level and lowest
cholesterol content has a viscosity of < 5 × 10
-6 kg/s
compared to < 10 × 10
-6 kg/s of Alveofact
®,w h i c hh a s
a high concentration of cholesterol and small amounts
Figure 3 Effect of Alveofact
® on viability and DNA synthesis. Cells were exposed to 10 mg/ml Alveofact
® for 0.5, 4.0 and 24 h as described.
A: Viability as percentage of control. B: DNA synthesis as percentage of control. Bars represent mean + SEM of 3 independent experiments. *
P<0.05 vs. control. MPII: mouse type II (iMATII) cells, RPII: rat type II cells.
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tions have been shown to have an inhibitory effect on
lymphocyte proliferative responses to mutagens, alloan-
tigen [22] and interleukin-2 [23,24]. Furthermore, sur-
factant affects immunoglobulin production by B cells
and cytotoxicity of natural killer cells [22]. Surfactant
interacts with macrophages [25] and inhibits cytokine
release [21,26] down regulates DNA-synthesis of fibro-
blasts[9] and suppresses the lymphocyte proliferation in
a concentration-dependent manner [8]. The latter effect
was different when large surfactant aggregates were
compared with small aggregates. While the former had
minimal effects on DNA synthesis, the latter exhibited a
bi-phasic response. The differences could be explained
by differences in lipid composition of different surfac-
tant subtypes [13,27].
Thus, it could be speculated, that differences found in
the present study are due to differences in lipid compo-
sition of the surfactant preparations, however, subse-
quent studies are required to prove this hypothesis.
Comparisons of biological effects of exogenous surfac-
tant in in-vitro models is often complicated by the fact
that different cells types and species were utilized in
each study.
Therefore, we carried out a single study with three
ATII cell culture models in order to investigate whether
or not such models are inherently different in their
responses. As the results show, the effect of exogenous
surfactant on viability or DNA synthesis can significantly
vary depending on the ATII cell culture model used. A
similar comparison has not been conducted previously.
However, whether these differences are species related
or cell model specific is difficult to clarify.
Clinical relevance of the results
Clinical data of a retrospective study that compare
infants treated with either Curosurf
® or Alveofact
® did
not show any differences in the incidence of chronic
lung disease [28]. Post mortem specimens of mechani-
cally ventilated preterm infants with RDS who required
supplemental oxygen and received exogenous surfactant
showed no alterations in proliferation of epithelial cells
when compared with lungs obtained from preterm
infants who did not receive exogenous surfactant [29].
Other authors did not find a histological differences in
lung specimens obtained from preterm infants who
received surfactant or were untreated [12,30]. However,
it is known, that surfactant treatment may accelerate
epithelial cell regeneration in preterm infants with RDS
significantly [31]. These seemingly contradictory results
could be due to different surfactant preparations or dif-
ferent time points after surfactant therapies that were
investigated. Whereas Gonda et al. focused on the early
repair process in infants less than 7 days of age the
other authors described long term effects. In conclusion,
this study supports the hypothesis that exogenous sur-
factant can affect pulmonary alveolar cell DNA synthesis
of extremely preterm infants, and that this effect is
potentially dependent on the type of surfactant and on
the duration of exposure.
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